Download PDF
Klin Padiatr 2012; 224(06): 377-381
DOI: 10.1055/s-0032-1323824
Original Article
© Georg Thieme Verlag KG Stuttgart · New York

Evaluation of the Prognostic Meaning of C-reactive Protein (CRP) in Children and Adolescents with Classical Hodgkin’s Lymphoma (HL)

Die prognostische Bedeutung des C-reaktiven Proteins bei Kindern und Jugendlichen mit klassischem Hodgkin Lymphom (HL)
R. Haase
1   Klinik für Kinder- und Jugendmedizin, Martin-Luther-Universität Halle Wittenberg, Halle/Saale, Germany
,
C. Vilser
1   Klinik für Kinder- und Jugendmedizin, Martin-Luther-Universität Halle Wittenberg, Halle/Saale, Germany
,
C. Mauz-Körholz
1   Klinik für Kinder- und Jugendmedizin, Martin-Luther-Universität Halle Wittenberg, Halle/Saale, Germany
,
D. Hasenclever
2   Institut für Medizinische Informatik, Statistik & Epidemiologie (IMISE), Universität Leipzig, Leipzig, Germany
,
R. Kluge
3   Klinik und Poliklinik für Nuklearmedizin, Universitätsklinikum Leipzig, Leipzig, Germany
,
K. Ruschke
4   Klinik für Radiologie, Halle/Saale, Martin-Luther-Universität Halle Wittenberg, Germany
,
A. Borkhardt
5   Zentrum für Kinder- und Jugendmedizin, Universität Düsseldorf, Düsseldorf, Germany
,
K. Seeger
6   Klinik für Pädiatrie mit Schwerpunkt Onkologie und Hämatologie, Charite Universitätsmedizin Berlin, Berlin, Germany
,
T. Lehrnbecher
7   Zentrum für Kinder- und Jugendmedizin, Klinik III, Klinikum der Johann-Wolfgang-Goethe-Universität, Frankfurt, Germany
,
A. Kulozik
8   Kinderklinik III: Päd. Onkologie, Hämatologie und Immunologie, Heidelberg, Universitätsklinikum Heidelberg, Germany
,
J. Rößler
9   Klinik IV: Pädiatrische Hämatologie und Onkologie, Universitätsklinikum Freiburg, ZKJ, Freiburg, Germany
,
S. Burdach
10   Kinderklinik München Schwabing, München, Technische Universität München, Germany
,
H. Jürgens
11   Pädiatrische Hämatologie und Onkologie, Univ.-Klinikum Münster, Klinik für Kinder- und Jugendmedizin, Münster, Germany
,
D. Körholz
1   Klinik für Kinder- und Jugendmedizin, Martin-Luther-Universität Halle Wittenberg, Halle/Saale, Germany
› Author Affiliations
Further Information

Publication History

Publication Date:
09 October 2012 (online)

Also available at
    Permissions and Reprints

Abstract

Background:

In adult cancer patients the negative predictive value of elevated CRP levels has been described for several malignancies. Only few studies have analyzed the prognostic role of CRP in children and adolescents with classical HL. In these studies elevated CRP levels correlate with the presence of classical risk factors and adverse outcome.

Patients and methods:

The prognostic role of CRP for patients with classical HL admitted to the GPOH-HD-2002 study was analyzed retrospectively.

Results:

CRP levels were documented for 369 of 573 patients. Significant (p<0.05) increased median CRP levels were found in the presence of B-Symptoms (25.7 vs. 5.1 mg/l), extranodal involvement (21.5 vs. 7.5 mg/l), elevated erythrocyte sedimentation rate (ESR, 13.0 vs. 1.0 mg/l) and stage III/IV disease (15.5 vs. 5.3 mg/l). 83.9% of patients with elevated and 45.8% of patients with normal CRP had an ESR >30 mm/h.

Conclusion:

Elevated CRP levels were associated with classical risk factors of HL. CRP and ESR may reflect different biological processes. CRP was prognostic within early stage TG-1 patients treated with reduced treatment, but not within advanced stage TG-2+3.

Zusammenfassung

Hintergrund:

Das C- reaktive Protein (CRP) wurde bei einer Vielzahl von malignen Erkrankungen des Erwachsenenalters als Risikofaktor beschrieben. Hinsichtlich des HL im Kindes- und Jugendalter existieren zur prognostischen Wertigkeit des CRP nur wenige Daten. Diese zeigen eine Korrelation von erhöhtem CRP und ungünstiger Prognose bzw. dem Vorliegen klassischer Risikofaktoren.

Patienten und Methoden:

In der vorliegenden Arbeit analysierten wir retrospektiv die prognostische Bedeutung des CRP für im Rahmen der GPOH-HD-2002 Studie behandelte Kinder und Jugendliche mit klassischem HL.

Ergebnisse:

CRP Werte waren für 369 von 573 Patienten verfügbar. Signifikant (p<0,05) erhöhte mediane CRP Werte fanden sich bei Vorliegen von B-Symptomen (25,7 vs. 5,1 mg/l), einer Blutsenkungsgeschwindigkeit >30 mm/h (13,0 vs. 1,0 mg/l), extranodalem Befall (21,5 vs. 7,5 mg/l) und Stadium III/IV (15,5 vs. 5,3 mg/l). 83,9% der Patienten mit erhöhtem und 45,8% der Patienten mit normalen CRP hatten eine BSG >30 mm/h. In der Therapiegruppe (TG) 1, nicht aber in TG 2 und 3 hatten Patienten mit initial erhöhtem CRP ein höheres Risiko für negatives outcome (Progression/Rezidiv oder Tod).

Schlussfolgerung:

In der analysierten Patientengruppe korreliert das CRP mit klassischen Risikofaktoren des HL. Die Entzündungsparameter CRP und BSG sind hinsichtlich der Prognoseabschätzung nicht austauschbar. Eine prognostische Bedeutung des CRP ließ sich nur für die TG 1 mit relativ geringer Therapieintensität nachweisen.

Key words

hodgkin’s lymphoma - c-reactive protein - prognosis - risk factor - GPOH-HD-2002 study

Schlüsselwörter

Hodgkin Lymphom - C-reaktives Protein - Prognose - Risikofaktor - GPOH-HD-2002 Studie
 

  • References

  • 1 Axdorph U, Sjoberg J, Grimfors G et al. Biological markers may add to prediction of outcome achieved by the International Prognostic Score in Hodgkin’s disease. Ann Oncol 2000; 11: 1405-1411
    CrossrefPubMedGoogle Scholar
  • 2 Bien E, Balcerska A. Serum soluble interleukin-2 receptor, beta2-microglobulin, lactate dehydrogenase and erythrocyte sedimentation rate in children with Hodgkin’s lymphoma. Scand J Immunol 2009; 70: 490-500
    CrossrefPubMedGoogle Scholar
  • 3 Bien E, Balcerska A, Adamkiewicz-Drozynska E et al. Pre-treatment serum levels of interleukin-10, interleukin-12 and their ratio predict response to therapy and probability of event-free and overall survival in childhood soft tissue sarcomas, Hodgkin’s lymphomas and acute lymphoblastic leukemias. Clin Biochem 2009; 42: 1144-1157
    CrossrefPubMedGoogle Scholar
  • 4 Carbone PP, Kaplan HS, Musshoff K et al. Report of the Committee on Hodgkin’s Disease Staging Classification. Cancer Res 1971; 31: 1860-1861
    PubMedGoogle Scholar
  • 5 Child JA, Spati B, Illingworth S et al. Serum beta 2 microglobulin and C-reactive protein in the monitoring of lymphomas: findings in a multicenter study and experience in selected patients. Cancer 1980; 45: 318-326
    CrossrefPubMedGoogle Scholar
  • 6 Debling D, Spix C, Blettner M et al. The cohort of long-term survivors at the German childhood cancer registry. Klin Padiatr 2008; 220: 371-377
    Article in Thieme ConnectPubMedGoogle Scholar
  • 7 Dorffel W, Luders H, Ruhl U et al. Preliminary results of the multicenter trial GPOH-HD 95 for the treatment of Hodgkin’s disease in children and adolescents: analysis and outlook. Klin Padiatr 2003; 215: 139-145
    Article in Thieme ConnectPubMedGoogle Scholar
  • 8 Fischer M, Bijman M, Molin D et al. Increased serum levels of interleukin-9 correlate to negative prognostic factors in Hodgkin’s lymphoma. Leukemia 2003; 17: 2513-2516
    CrossrefPubMedGoogle Scholar
  • 9 Funovics PT, Edelhauser G, Funovics MA et al. Pre-operative serum C-reactive protein as independent prognostic factor for survival but not infection in patients with high-grade osteosarcoma. Int Orthop 2011; 35: 1529-1536
    CrossrefPubMedGoogle Scholar
  • 10 Garcia R, Hernandez JM, Caballero MD et al. Serum lactate dehydrogenase level as a prognostic factor in Hodgkin’s disease. Br J Cancer 1993; 68: 1227-1231
    CrossrefPubMedGoogle Scholar
  • 11 Gause A, Roschansky V, Tschiersch A et al. Low serum interleukin-2 receptor levels correlate with a good prognosis in patients with Hodgkin’s lymphoma. Ann Oncol 1991; 2 (Suppl. 02) 43-47
    PubMedGoogle Scholar
  • 12 Han Y, Mao F, Wu Y et al. Prognostic role of C-reactive protein in breast cancer: a systematic review and meta-analysis. Int J Biol Markers 2011; 26: 209-215
    PubMedGoogle Scholar
  • 13 Hasenclever D. The disappearance of prognostic factors in Hodgkin’s disease. Ann Oncol 2002; 13 (Suppl. 01) 75-78
    CrossrefPubMedGoogle Scholar
  • 14 Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin’s disease. International Prognostic Factors Project on Advanced Hodgkin’s Disease. N Engl J Med 1998; 339: 1506-1514
    CrossrefPubMedGoogle Scholar
  • 15 Heikkila K, Ebrahim S, Lawlor DA. A systematic review of the association between circulating concentrations of C reactive protein and cancer. J Epidemiol Community Health 2007; 61: 824-833
    CrossrefPubMedGoogle Scholar
  • 16 Heinrich PC, Castell JV, Andus T. Interleukin-6 and the acute phase response. Biochem J 1990; 265: 621-636
    PubMedGoogle Scholar
  • 17 Hong S, Kang YA, Cho BC et al. Elevated serum C-reactive protein as a prognostic marker in small cell lung cancer. Yonsei Med J 2012; 53: 111-117
    CrossrefPubMedGoogle Scholar
  • 18 Kelley TW, Pohlman B, Elson P et al. The ratio of FOXP3+ regulatory T cells to granzyme B+ cytotoxic T/NK cells predicts prognosis in classical Hodgkin lymphoma and is independent of bcl-2 and MAL expression. Am J Clin Pathol 2007; 128: 958-965
    CrossrefPubMedGoogle Scholar
  • 19 Kelly KM. Management of children with high-risk Hodgkin lymphoma. Br J Haematol 2012; 157: 3-13
    CrossrefPubMedGoogle Scholar
  • 20 Khandavilli SD, Ceallaigh PO, Lloyd CJ et al. Serum C-reactive protein as a prognostic indicator in patients with oral squamous cell carcinoma. Oral Oncol 2009; 45: 912-914
    CrossrefPubMedGoogle Scholar
  • 21 Klimm B, Engert A. Combined modality treatment of Hodgkin’s lymphoma. Cancer J 2009; 15: 143-149
    CrossrefPubMedGoogle Scholar
  • 22 Kluge R, Korholz D. Role of FDG-PET in Staging and Therapy of Children with Hodgkin Lymphoma. Klin Padiatr 2011; 223: 315-319
    Article in Thieme ConnectPubMedGoogle Scholar
  • 23 Kurzrock R, Redman J, Cabanillas F et al. Serum interleukin 6 levels are elevated in lymphoma patients and correlate with survival in advanced Hodgkin’s disease and with B symptoms. Cancer Res 1993; 53: 2118-2122
    PubMedGoogle Scholar
  • 24 Lawrenz B, Henes M, Neunhoeffer E et al. Fertility preservation in girls and adolescents before chemotherapy and radiation – review of the literature. Klin Padiatr 2011; 223: 126-130
    Article in Thieme ConnectPubMedGoogle Scholar
  • 25 Legouffe E, Rodriguez C, Picot MC et al. C-reactive protein serum level is a valuable and simple prognostic marker in non Hodgkin’s lymphoma. Leuk Lymphoma 1998; 31: 351-357
    PubMedGoogle Scholar
  • 26 Mauz-Korholz C, Hasenclever D, Dorffel W et al. Procarbazine-free OEPA-COPDAC chemotherapy in boys and standard OPPA-COPP in girls have comparable effectiveness in pediatric Hodgkin’s lymphoma: the GPOH-HD-2002 study. J Clin Oncol 2010; 28: 3680-3686
    CrossrefPubMedGoogle Scholar
  • 27 Nakamura T, Matsumine A, Matsubara T et al. Clinical significance of pretreatment serum C-reactive protein level in soft tissue sarcoma. Cancer 2012; 118: 1055-1061
    CrossrefPubMedGoogle Scholar
  • 28 Nozoe T, Saeki H, Sugimachi K. Significance of preoperative elevation of serum C-reactive protein as an indicator of prognosis in esophageal carcinoma. Am J Surg 2001; 182: 197-201
    CrossrefPubMedGoogle Scholar
  • 29 Saito K, Kihara K. Role of C-reactive protein as a biomarker for renal cell carcinoma. Expert Rev Anticancer Ther 2010; 10: 1979-1989
    CrossrefPubMedGoogle Scholar
  • 30 Saito K, Kihara K. C-reactive protein as a biomarker for urological cancers. Nat Rev Urol 2011; 8: 659-666
    Google Scholar
  • 31 Steidl C, Lee T, Shah SP et al. Tumor-associated macrophages and survival in classic Hodgkin’s lymphoma. N Engl J Med 2010; 362: 875-885
    CrossrefPubMedGoogle Scholar
  • 32 von Tresckow B, Plutschow A, Fuchs M et al. Dose-Intensification in Early Unfavorable Hodgkin’s Lymphoma: Final Analysis of the German Hodgkin Study Group HD14 Trial. J Clin Oncol 2012; 30: 907-913
    CrossrefPubMedGoogle Scholar
  • 33 Wieland A, Kerbl R, Berghold A et al. C-reactive protein (CRP) as tumor marker in pediatric and adolescent patients with Hodgkin disease. Med Pediatr Oncol 2003; 41: 21-25
    CrossrefPubMedGoogle Scholar
  • 34 Zielinski CC, Preis P, Aiginger P et al. Acute-phase-proteins and parameters of humoral immunity in patients with advanced Hodgkin’s disease. J Cancer Res Clin Oncol 1985; 110: 65-70
    CrossrefPubMedGoogle Scholar